Suven Secures Product Patents in New Zealand, Sri Lanka | CORPORATE ETHOS

Suven Secures Product Patents in New Zealand, Sri Lanka

By: | September 14, 2018
suven life sciences

Sep 14: Hyderabad-based biopharma firm Suven Life Sciences Ltd on Friday announced that it has been granted one product patent from New Zealand (728918) and another one product patent from Sri Lanka (17300) corresponding to the New Chemical Entity for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2034 and 2031 respectively.

According to the company, the granted claims of the patents include the class of selective 5-HT4 and H3 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia and sleep disorders like Narcolepsy etc.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.